Eloxx Stock Story

ELOX
 Stock
  

USD 0.42  0.02  5.00%   

Let's try to break down what's happening with Eloxx Pharmaceuticals amid unprecedented political, and economic uncertainty. Eloxx Pharmaceuticals is currently traded for 0.33. The entity has historical hype elasticity of -0.01. The average price elasticity to hype of competition is about 0.25. The firm is estimated to decline in value after the next headline, with the price expected to drop to 0.32. The average volatility of media hype impact on the company stock price is huge, making predictions on the news or social media along less reliable. The price decrease on the next news is expected to be -3.03%, whereas the daily expected return is currently at -0.51 percent. The volatility of related hype on Eloxx Pharmaceuticals is about 939.83% with expected price after next announcement by competition of 0.58 Given the investment horizon of 90 days the next estimated press release will be very soon.
Published over three months ago
View all stories for Eloxx Pharmaceuticals | View All Stories

Thinking to buy more of Eloxx Pharmaceuticals (NASDAQ:ELOX)?

The firm shows a Beta (market volatility) of 0.5925, which means possible diversification benefits within a given portfolio. Let's try to break down what Eloxx's beta means in this case. As returns on the market increase, Eloxx Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Eloxx Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Eloxx Pharmaceuticals historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards predicting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Eloxx Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Eloxx Pharmaceuticals has an expected return of -0.51%. Please be advised to confirm Eloxx Pharmaceuticals coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Eloxx Pharmaceuticals performance from the past will be repeated at some point in the near future.
The successful prediction of Eloxx Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Eloxx Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Eloxx Pharmaceuticals based on Eloxx Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Eloxx Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Eloxx Pharmaceuticals's related companies.

Watch out for price decline

Please consider monitoring Eloxx Pharmaceuticals on a daily basis if you are holding a position in it. Eloxx Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Eloxx Pharmaceuticals stock to be traded above the $1 level to remain listed. If Eloxx Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Use Technical Analysis to project Eloxx expected Price

Eloxx Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Eloxx Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Eloxx Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How does Eloxx utilize its cash?

To perform a cash flow analysis of Eloxx Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Eloxx Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Eloxx Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Eloxx Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Eloxx Pharmaceuticals reported Net Cash Flow from Operations of (35 Million) in 2021

Acquisition by Androski Lindsay of 40000 shares of Eloxx Pharmaceuticals subject to Rule 16b-3

Legal trades by Eloxx Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Eloxx insider trading alert for grant of stock options (right to buy) by Androski Lindsay, the corporate stakeholder, on 6th of July 2022. This event was filed by Eloxx Pharmaceuticals Inc with SEC on 2022-07-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at Eloxx

The company reported the previous year's revenue of 211.9 K. Net Loss for the year was (60.76 M) with profit before overhead, payroll, taxes, and interest of 211.9 K.

Revenues Breakdown

Eloxx Pharmaceuticals Revenues yearly trend continues to be fairly stable with very little volatility. Revenues is likely to outpace its year average in 2022. Revenues usually refers to amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses. Eloxx Pharmaceuticals Revenues is fairly stable at the moment as compared to the past year. Eloxx Pharmaceuticals reported Revenues of 90,000 in 2021
2010
2012
2021
2022
2010200,000
2012100,000
202190,000
2022110,526

Chances of Eloxx Pharmaceuticals investors to go out of control

The mean deviation is down to 3.52 as of today.
As of the 7th of May, Eloxx Pharmaceuticals shows the mean deviation of 3.52, and Coefficient Of Variation of (891.68). Eloxx Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Eloxx Pharmaceuticals, which can be compared to its rivals. Please confirm Eloxx Pharmaceuticals coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Eloxx Pharmaceuticals is priced favorably, providing market reflects its regular price of 0.33 per share. As Eloxx Pharmaceuticals appears to be a penny stock we also advise to verify its total risk alpha numbers.

The Bottom Line

While some other entities in the biotechnology industry are either recovering or due for a correction, Eloxx may not be as strong as the others in terms of longer-term growth potentials. All things considered, as of the 7th of May 2022, our concluding 90 days buy-hold-sell advice on the company is Cautious Hold. We believe Eloxx Pharmaceuticals is currently undervalued with very high probability of distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Eloxx Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com